

Maria Gazouli, Professor of Biology - Genetics - Nanomedicine, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens (NKUA), Greece



Dr. Maria Gazouli is a Biologist and Professor at the Medical School of NKUA. She is certified in Laboratory Genetics by the Ministry of Health of Greece. She earned her first PhD from the Department of Biology at NKUA in collaboration with the Hellenic Pasteur Institute, and her second PhD from the Department of Microbiology, Medical School, NKUA. She completed postdoctoral training in Cell Biology and Pharmacology at Georgetown University School of Medicine in Washington, DC. Her research focuses on the molecular/genetic basis of autoimmune/inflammatory diseases and cancer, molecular detection of pathogens, and disease pathogenesis. She also works on nanotechnology applications in cancer detection, imaging, and targeted drug delivery. Dr. Gazouli received a Fulbright Scholarship for nanotechnology-based biosensor arrays for colorectal cancer cell detection at the University of Maryland, College Park, and further training at Northeastern University in Boston on targeted drug delivery using nanotechnology.

She has authored over 400 international publications with more than 17,800 citations (h-index: 66, Google Scholar), holds one international and three European patents, and has given over 70 invited lectures worldwide. She has mentored numerous young scientists, serves as editor and peer reviewer for several scientific journals, and is an evaluator for national and international research funding bodies.

Dr. Gazouli coordinates EU- and nationally-funded research programs and led the European Joint Action on Rare Cancers with over 20 research groups across Europe.

She teaches Biology, Genetics, and Nanomedicine at undergraduate and postgraduate levels at NKUA and other universities in Greece and abroad. She has also contributed to Greek textbooks in these fields. Additionally, Dr. Gazouli, serves as the scientific lead and partner for multiple European and national research projects.

She has served as a Board Member of the National Organization for Medicines (EOF, 2019–2023), National Representative to the EMA's Committee for Advanced Therapies (CAT, 2021–present), and is currently a member of the Governing Committee of the Central Health Council (KESY, 2023–present), and is a member of the Greek National Authority for Medically Assisted Reproduction (2024 – present)

ORCID ID: 0000-0002-3295-6811 ResearcherID: I-2572-2018

Representative Publications

1. Liquid Polycaprolactone (PCL) for Reversing PXE's Skin Laxity of Inner Thighs and Knees: A Case Report. Dimonitsas E, Albanopoulou A, Neamonitou F, Lakiotaki E, Korkolopoulou P, **Gazouli M**. *J Cosmet Dermatol*. 2025 Feb;24(2):e16713. doi: 10.1111/jocd.16713
2. Chemotherapeutic Drug Delivery Nanoplatfrom Development: From Physicochemical to Preclinical Evaluation. Kontogiannis O, Selianitis D, Palikaras K, Pippa N, Pispas S, Efsthathopoulos E, **Gazouli M**. *Int J Mol Sci*. 2024 Oct 26;25(21):11520. doi: 10.3390/ijms252111520
3. Altered Expression of Neuroplasticity-Related Genes in Alcohol Addiction and Treatment. Legaki E, Dovrolis N, Moscholiou N, Koutromanos I, Vassilopoulos E, Dakanalis A, **Gazouli M**, Tzavellas E. *Int J Mol Sci*. 2024 Oct 22;25(21):11349. doi: 10.3390/ijms252111349.
4. Insights into Therapeutic Response Prediction for Ustekinumab in Ulcerative Colitis Using an Ensemble Bioinformatics Approach. Koustenis K, Dovrolis N, Viazis N, Ioannou A, Bamias G, Karamanolis G, **Gazouli M**. *Int J Mol Sci*. 2024 May 18;25(10):5532. doi: 10.3390/ijms25105532.
5. Dysbiosis Signature of Fecal Microbiota in Patients with Pancreatic Adenocarcinoma and Pancreatic Intraductal Papillary Mucinous Neoplasms. Sidiropoulos T, Dovrolis N, Katifelis H, Michalopoulos NV, Kokoropoulos P, Arkadopoulos N, **Gazouli M**. *Biomedicines*. 2024 May 8;12(5):1040. doi: 10.3390/biomedicines12051040
6. Inflammation and Immunity Gene Expression Patterns and Machine Learning Approaches in Association with Response to Immune-Checkpoint Inhibitors-Based Treatments in Clear-Cell Renal Carcinoma. Dovrolis N, Katifelis H, Grammatikaki S, Zakopoulou R, Bamias A, Karamouzis MV, Souliotis K, **Gazouli M**. *Cancers (Basel)*. 2023 Nov 29;15(23):5637. doi: 10.3390/cancers15235637.
7. Identifying Microbiome Dynamics in Pediatric IBD: More than a Family Matter. Dovrolis N, Moschoviti A, Fessatou S, Karamanolis G, Kolios G, **Gazouli M**. *Biomedicines*. 2023 Jul 13;11(7):1979. doi: 10.3390/biomedicines11071979.
8. Circulating miRNA Expression Profiling in Breast Cancer Molecular Subtypes: Applying Machine Learning Analysis in Bioinformatics. Triantafyllou A, Dovrolis N, Zografos E, Theodoropoulos C, Zografos GC, Michalopoulos NV, **Gazouli M**. *Cancer Diagn Progn*. 2022 Nov 3;2(6):739-749. doi: 10.21873/cdp.10169. eCollection 2022 Nov-Dec.
9. **Gazouli M**, Wouters MM, Kapur-Pojskić L, Bengtson MB, Friedman E, Nikčević G, Demetriou CA, Mulak A, Santos J, Niesler B: Lessons learned—resolving the enigma of genetic factors in IBS. *Nat Rev Gastroenterol Hepatol*, 13(2):77-87, 2016.

10. **Gazouli M**, Zacharatos P, Gorgoulis V, Mantzaris G, Papalambros E, Ikonomopoulos J. The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population. *Gastroenterology* 126(1):367-9, 2004.